Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens

被引:55
作者
Schmid, M
Kreil, A
Jessner, W
Homoncik, M
Datz, C
Gangl, A
Ferenci, P
Peck-Radosavljevic, M
机构
[1] Univ Vienna, Dept Internal Med 4, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria
[2] KH Oberndorf, Dept Internal Med, Salzburg, Austria
关键词
D O I
10.1136/gut.2004.057893
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has haematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on haematopoiesis. Methods: Haematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-alpha 2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-alpha 2a (group C), or pegylated IFN-alpha 2b (group D) in combination with ribavirin. Results: At week 4, haemoglobin levels were diminished in all groups receiving combination therapy. In the monotherapy group, haemoglobin decreased slightly after eight weeks. In all groups, haemoglobin remained diminished throughout therapy. In all patients, leucocytes (while blood cells) decreased after four weeks and remained low during treatment. Platelets (peripheral platelet count (PPC)) were decreased in all groups after four weeks and remained below baseline levels during therapy in group A, C, and D whereas in group B PPC recovered early and reached baseline levels at week 16 of therapy. Concomitantly with the decreases in haemoglobin and PPC, erythropoietin increased in all groups receiving combination therapy and thrombopoietin in all groups. Patients treated with pegylated IFN-alpha 2a and those who received pegylated IFN-alpha 2b combination therapy differed only in leucopoiesis, whereas erythropoiesis and thrombopoiesis were comparable. Conclusion: IFN-alpha based therapies are associated with a decrease in all three haematopoietic lineages, irrespective of the type of therapy used. The stronger suppressive effect of pegylated IFN-alpha 2a on leucopoiesis could be due to a dose effect. Overall, concentrations of endogenous haematopoietic growth factors are increased but can only partially alleviate haematotoxicity. Potential uses of exogenous haematopoietic growth factors and their impact on the virological response need to be explored.
引用
收藏
页码:1014 / 1020
页数:7
相关论文
共 48 条
[11]   Rapid onset of hematotoxic effects after interferon alpha in hepatitis C [J].
Dormann, H ;
Krebs, S ;
Muth-Selbach, U ;
Brune, K ;
Schuppan, D ;
Hahn, EG ;
Schneider, HT .
JOURNAL OF HEPATOLOGY, 2000, 32 (06) :1041-1042
[12]   Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study [J].
Dusheiko, G ;
Main, J ;
Thomas, H ;
Reichard, O ;
Lee, C ;
Dhillon, A ;
Rassam, S ;
Fryden, A ;
Reesink, H ;
Bassendine, M ;
Norkrans, G ;
Cuypers, T ;
Lelie, N ;
Telfer, P ;
Watson, J ;
Weegink, C ;
Sillikens, P ;
Weiland, O .
JOURNAL OF HEPATOLOGY, 1996, 25 (05) :591-598
[13]   CHANGES IN THE BONE-MARROW OF CANCER-PATIENTS TREATED WITH RECOMBINANT INTERFERON ALPHA-2 [J].
ERNSTOFF, MS ;
KIRKWOOD, JM .
AMERICAN JOURNAL OF MEDICINE, 1984, 76 (04) :593-596
[14]   A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon [J].
Fattovich, G ;
Giustina, G ;
Favarato, S ;
Ruol, A ;
Macarri, G ;
Orlandi, F ;
Iaquinto, G ;
Ambrosone, L ;
Francavilla, A ;
Pastore, G ;
Santantonio, MT ;
Romagno, D ;
Bolondi, L ;
Sofia, S ;
Marchesini, A ;
Pisi, E ;
Mazzella, G ;
Roda, E ;
Attaro, L ;
Chiodo, F ;
Mori, F ;
Verucchi, G ;
Lanzini, A ;
Salmi, A ;
Calvi, B ;
Bozzetti, F ;
Radaeli, E ;
Bernasconi, M ;
Pilleri, G ;
Bacca, D ;
Romano, G ;
Mastrapasqua, G ;
Cozzolongo, R ;
Cacopardo, B ;
Nunnari, A ;
Blasi, A ;
Sala, LO ;
Minoli, G ;
Sangiovanni, A ;
Spinzi, GC ;
Colombo, A ;
Camassa, M ;
Riva, D ;
Maggi, G ;
Boccia, S ;
Gualandi, G ;
Nucci, A ;
Pacini, F ;
Marino, N ;
Mazzotta, F .
JOURNAL OF HEPATOLOGY, 1996, 24 (01) :38-47
[15]   Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients [J].
Fattovich, G ;
Giustina, G ;
Degos, F ;
Tremolada, F ;
Diodati, G ;
Almasio, P ;
Nevens, F ;
Solinas, A ;
Mura, D ;
Brouwer, JT ;
Thomas, H ;
Njapoum, C ;
Casarin, C ;
Bonetti, P ;
Fuschi, P ;
Basho, J ;
Tocco, A ;
Bhalla, A ;
Galassini, R ;
Noventa, F ;
Schalm, SW ;
Realdi, G .
GASTROENTEROLOGY, 1997, 112 (02) :463-472
[16]   Combination of interferon induction therapy and ribavirin in chronic hepatitis C [J].
Ferenci, P ;
Brunner, H ;
Nachbaur, K ;
Datz, C ;
Gschwantler, M ;
Hofer, H ;
Stauber, R ;
Hackl, F ;
Jessner, W ;
Rosenbeiger, M ;
Munda-Steindl, P ;
Hegenbarth, K ;
Gangl, A ;
Vogel, W .
HEPATOLOGY, 2001, 34 (05) :1006-1011
[17]   Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin:: final results of a prospective randomized trial [J].
Ferenci, P ;
Stauber, R ;
Steindl-Munda, P ;
Gschwantler, M ;
Fickert, P ;
Datz, C ;
Müller, C ;
Hackl, F ;
Rainer, W ;
Watkins-Riedel, T ;
Lin, W ;
Krejs, GJ ;
Gangl, A .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (06) :699-705
[18]   Regulation of thrombopoietin levels by c-mpl - Mediated binding to platelets [J].
Fielder, PJ ;
Gurney, AL ;
Stefanich, E ;
Marian, M ;
Moore, MW ;
CarverMoore, K ;
deSauvage, FJ .
BLOOD, 1996, 87 (06) :2154-2161
[19]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[20]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244